ArticleSmall methods2026
Regularized Single-Cell Imaging Enables Generalizable AI Models for Stain-Free Cell Viability Screening.
Article in Small methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cell viability assays are essential tools in biomedical research and drug development. Artificial intelligence (AI) offers the potential to simplify these assays by predicting cell viability directly from brightfield microscopy images, but current models lack generalizability across diverse cell types and treatments. Here, we introduce a strategy called "regularized imaging", where single cells are isolated in nanowells to generate standardized image patches that simplify segmentation and improve training data quality. We trained our model using example images of live and dead cells from a single cell line exposed to four cytotoxic conditions (ethanol, andrographolide, daunorubicin, and serum starvation). Despite this narrow training dataset, the resulting model accurately identified live and dead cells after treatments by previously unseen compounds, successfully replicating dose-response curves comparable to fluorescence live/dead assays. Importantly, this model effectively generalized across diverse cell types, including both adherent and suspension cells. Additionally, microscopy-based cell viability analysis is non-destructive, enabling repeated measurements to perform kinetic studies to distinguish between fast- and slow-acting compounds. Our findings highlight how regularized single-cell imaging enables the training of broadly generalizable AI models to recognize biologically relevant cell features for label-free cell screening workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.